NCT01282463 · REGISTRY CONDITION SEARCH

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2019-09-09

This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docetaxel and ramucirumab; or docetaxel and icrucumab.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

Percentage of Participants Achieving Objective Response Rate (ORR)

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Number of Participants With Adverse Events (AEs)

→

outcome · POSTED

Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab

→

outcome · POSTED

PK: Minimum Concentration (Cmin) Ramucirumab

→

outcome · POSTED

PK: Cmax Icrucumab

→

outcome · POSTED

PK: Cmin Icrucumab

→

outcome · POSTED

Number of Participants With Serum Anti-Ramucirumab Antibody Assessment

→

outcome · POSTED

Number of Participants With Serum Anti-Icrucumab Antibody Assessment

→

outcome · POSTED

Pharmacodynamics (PD): Change in Circulating Levels of Placental Growth Factor (PlGF)

→

outcome · POSTED

PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-A (VEGF-A)

→

outcome · POSTED

PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-B (VEGF-B)

→

outcome · POSTED

PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-1 (VEGFR-1)

→

outcome · POSTED

PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-2 (VEGFR-2)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically or cytologically confirmed transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis * Locally advanced or metastatic and unresectable transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis * Had treatment with a platinum-containing regimen * Disease progression within 12 months of after receiving the last dose of a platinum containing regimen in the neoadjuvant or adjuvant setting, and/or had disease progression while on a platinum-containing regimen or within 12 months after the last dose of therapy in the locally advanced or metastatic setting * Has measurable or nonmeasurable disease * Life expectancy of ≥ 3 months * Received no more than 2 prior systemic chemotherapy regimens in any setting * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Has adequate hematologic, coagulation, hepatic and renal function * Does not have: * cirrhosis at a level of Child-Pugh B (or worse) * cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis * If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method during and for 12 weeks after the treatment period * If male, the patient is surgically sterile or compliant with a contraceptive regimen during and for 12 weeks after the treatment period Exclusion Criteria: * Received more than one prior systemic treatment regimen for metastatic disease * Received prior systemic taxane therapy (except for prior paclitaxel therapy) for Transitional Cell Carcinoma of the bladder, urethra, ureter, or renal pelvis in any setting (neoadjuvant, adjuvant, metastatic). Prior intravesical taxane therapy is allowed * Has received more than one prior anti-angiogenic agent for Transitional Cell Carcinoma of the bladder, urethra, ureter, or renal pelvis * Has received radiation therapy within 4 weeks prior to randomization * Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders * Has experienced a Grade ≥ 3 bleeding event (eg, via gastric ulcers, gastric varices, or gross hematuria) within 3 months prior to randomization * Has uncontrolled intercurrent illness including, but not limited to symptomatic anemia, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders * Has experienced any arterial thrombotic or thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack or cerebrovascular accident, within 6 months prior to randomization * Has known brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease * Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy * Has known human immunodeficiency virus infection or acquired immunodeficiency syndrome * Has received a prior autologous or allogeneic organ or tissue transplantation * Received chemotherapy within 21 days prior to randomization; and/or is currently enrolled in, or discontinued within 21 days prior to randomization from, a clinical trial involving an investigational product or unapproved use of a drug or device (other than the study drug\[s\] used in this study), or is concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study; and/or was treated with anti-angiogenic therapy within 28 days prior to randomization * Has undergone major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization * Has had a serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization * Has an elective or planned major surgery to be performed during the course of the trial * Is pregnant or lactating * Has a concurrent active malignancy other than adequately treated non-melanomatous skin cancer, curatively treated cervical carcinoma in-situ, other noninvasive carcinoma or in-situ neoplasm, or prostate cancer with an undetectable prostate specific antigen (PSA) and no current treatment with hormone therapy * Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention * History of gastrointestinal perforation and/or fistula within 6 months prior to randomization * Has active diverticulitis * Known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80 * Known hypersensitivity to agents of similar biologic composition as ramucirumab DP, IMC-18F1, or other agents that specifically target vascular endothelial growth factor receptor (VEGF)
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
intervention Names
Drug: Docetaxel
label
Docetaxel
type
ACTIVE_COMPARATOR
description
Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
intervention Names
Drug: Docetaxel
Biological: Ramucirumab DP
label
Docetaxel + Ramucirumab DP
type
EXPERIMENTAL
description
Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
intervention Names
Drug: Docetaxel
Biological: Icrucumab
label
Docetaxel + Icrucumab
type
EXPERIMENTAL

interventions

arm Group Labels
Docetaxel
Docetaxel + Icrucumab
Docetaxel + Ramucirumab DP
description
Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
name
Docetaxel
type
DRUG
arm Group Labels
Docetaxel + Ramucirumab DP
description
Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
name
Ramucirumab DP
other Names
IMC-1121B
LY3009806
type
BIOLOGICAL
arm Group Labels
Docetaxel + Icrucumab
description
12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
name
Icrucumab
other Names
IMC-18F1
LY3012212
type
BIOLOGICAL

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 148
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.
measure
Progression-Free Survival (PFS)
time Frame
Randomization to Measured PD or Death From Any Cause (Up To 40 Months)

secondary Outcomes

description
Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \[if tumor markers were initially above the upper limit of normal (ULN)\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\*100.
measure
Percentage of Participants Achieving Objective Response Rate (ORR)
time Frame
Randomization to Measured PD (Up to 40 Months)
description
The duration of response was measured from the time measurement criteria were first met for a CR or PR (whichever was first recorded) until the first date of objectively documented progressive disease (taking as a reference for progressive disease the smallest measurement recorded since randomization) or the date of death, whichever occurred first. Data for participants who did not relapse or die were censored at the day of their last adequate tumor assessment. Duration of response was estimated by the Kaplan-Meier method.
measure
Duration of Response
time Frame
First Criteria Met for CR or PR to Measured PD or Death From Any Cause (Up to 40 Months)
description
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
measure
Number of Participants With Adverse Events (AEs)
time Frame
Up To 41.7 Months
measure
Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab
time Frame
Cycle 1:Predose,1 hour(hr) post End of Infusion (EOI),48hr,72hr,168hr,336hr post-EOI;Cycle2:Predose,1hr post-EOI; Cycle3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI; Cycle4:Predose,1hr post-EOI;Cycle6 and every other cycle thereafter:Predose,1hr Post EOI
measure
PK: Minimum Concentration (Cmin) Ramucirumab
time Frame
Cycle 2:Predose,1hr post-EOI;Cycle3:Predose,1hr,48hr,72hr,168hr,336hr, post-EOI;Cycle4:Predose,1hr post-EOI;Cycle6:Predose,1hr Post EOI
measure
PK: Cmax Icrucumab
time Frame
Cycle 1:Predose,1 hr post-EOI, 48hr, 72hr Post-EOI; Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
measure
PK: Cmin Icrucumab
time Frame
Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
description
Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.
measure
Number of Participants With Serum Anti-Ramucirumab Antibody Assessment
time Frame
Cycle 1:Predose,EOI,1hr,48hr,72hr,168hr,336 hr post-EOI:Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI;Cycle 4:Predose,1hr post-EOI;Cycle 6:Predose,1hr post-EOI
description
A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals.
measure
Number of Participants With Serum Anti-Icrucumab Antibody Assessment
time Frame
Cycle 1 Day 1 and Day 8 Predose and 1hr Post Dose
measure
Pharmacodynamics (PD): Change in Circulating Levels of Placental Growth Factor (PlGF)
time Frame
40 months
measure
PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-A (VEGF-A)
time Frame
40 months
measure
PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-B (VEGF-B)
time Frame
40 months

Full study description

brief Summary: This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docetaxel and ramucirumab; or docetaxel and icrucumab.

Source references

references

citation
Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 May 1;34(13):1500-9. doi: 10.1200/JCO.2015.65.0218. Epub 2016 Feb 29.
pmid
26926681
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f66f6fe8b059cc622689
requested nct id
NCT01282463
primary nct id
NCT01282463
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Urethral+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
payload sha256
9ddb23593ef6ef3cb5b79961a5c143df0728c7d1f6d351ca2c9c51f51e4b1b64
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f66f6fe8b059cc622689
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01282463
occurrences
context exact
NCT01282463
end
11
exact text
NCT01282463
start
0
offset unit
unicode_code_points
query cond
Urethral Cancer
query disease state id
ds-urethral-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-urethral-cancer-000.json
source file sha256
308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
source json pointer
/studies/30/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
73a9e84f78b990590e72212895f9ec882477bc5ac39b51c026887fc743bb487f
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Urethral+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice